Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

160 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.
Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK. Oksvold MP, et al. Among authors: smeland eb. Sci Rep. 2021 Mar 18;11(1):6317. doi: 10.1038/s41598-021-85613-8. Sci Rep. 2021. PMID: 33737576 Free PMC article.
Combinatorial CAR design improves target restriction.
Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S. Köksal H, et al. Among authors: smeland eb. J Biol Chem. 2020 Dec 3;296:100116. doi: 10.1074/jbc.RA120.016234. Online ahead of print. J Biol Chem. 2020. PMID: 33234592 Free PMC article.
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series.
Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H. Wise JF, et al. Among authors: smeland eb. Blood Adv. 2020 May 12;4(9):1859-1866. doi: 10.1182/bloodadvances.2019001325. Blood Adv. 2020. PMID: 32374878 Free PMC article.
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S. Köksal H, et al. Among authors: smeland eb. Blood Adv. 2019 Apr 23;3(8):1230-1243. doi: 10.1182/bloodadvances.2018029678. Blood Adv. 2019. PMID: 30979721 Free PMC article.
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M. Steen CB, et al. Among authors: smeland eb. Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7. Haematologica. 2019. PMID: 30846496 Free PMC article. Clinical Trial. No abstract available.
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH. Josefsson SE, et al. Among authors: smeland eb. Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18. Cancer Immunol Res. 2019. PMID: 30659053 Free PMC article.
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A. Holte H, et al. Among authors: smeland eb. Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6. Br J Haematol. 2018. PMID: 30080252 Free PMC article. Clinical Trial.
160 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page